期刊
BIOMEDICINES
卷 10, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10010001
关键词
temozolomide; glioblastoma; pharmacology; site of action; quantification; omics
资金
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [404521405, SFB 1389-UNITE]
- UNITE Innovation Fund 2020
This article summarizes the ADME parameters and modes of action of Temozolomide (TMZ), and provides methodological options to monitor TMZ at its anatomical, cellular, and molecular sites of action (SOAs). The focus is on mass spectrometry-based approaches, with considerations given to avoiding artifacts in the analysis.
Temozolomide (TMZ), together with bulk resection and focal radiotherapy, is currently a standard of care for glioblastoma. Absorption, distribution, metabolism, and excretion (ADME) parameters, together with the mode of action of TMZ, make its biochemical and biological action difficult to understand. Accurate understanding of the mode of action of TMZ and the monitoring of TMZ at its anatomical, cellular, and molecular sites of action (SOAs) would greatly benefit precision medicine and the development of novel therapeutic approaches in combination with TMZ. In the present perspective article, we summarize the known ADME parameters and modes of action of TMZ, and we review the possible methodological options to monitor TMZ at its SOAs. We focus our descriptions of methodologies on mass spectrometry-based approaches, and all related considerations are taken into account regarding the avoidance of artifacts in mass spectrometric analysis during sampling, sample preparation, and the evaluation of results. Finally, we provide an overview of potential applications for precision medicine and drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据